CBAVE Stock Overview
A medical company, operates a network of ophthalmology clinics. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Clínica Baviera, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.70 |
| 52 Week High | €27.70 |
| 52 Week Low | €27.70 |
| Beta | 0.67 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 151.82% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| CBAVE | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 2.2% |
| 1Y | n/a | -22.7% | 9.0% |
Return vs Industry: Insufficient data to determine how CBAVE performed against the UK Healthcare industry.
Return vs Market: Insufficient data to determine how CBAVE performed against the UK Market.
Price Volatility
| CBAVE volatility | |
|---|---|
| CBAVE Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: CBAVE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CBAVE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,326 | Eduardo Baviera Sabater | www.clinicabaviera.com |
Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, cornea, neuroftalmología, and vías lagrimales treatments.
Clínica Baviera, S.A. Fundamentals Summary
| CBAVE fundamental statistics | |
|---|---|
| Market cap | €493.96m |
| Earnings (TTM) | €38.41m |
| Revenue (TTM) | €243.31m |
12.9x
P/E Ratio2.0x
P/S RatioIs CBAVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBAVE income statement (TTM) | |
|---|---|
| Revenue | €243.31m |
| Cost of Revenue | €122.92m |
| Gross Profit | €120.39m |
| Other Expenses | €81.98m |
| Earnings | €38.41m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.36 |
| Gross Margin | 49.48% |
| Net Profit Margin | 15.79% |
| Debt/Equity Ratio | 1.9% |
How did CBAVE perform over the long term?
See historical performance and comparison